Latest news
Aurigene and Debiopharm Group™ report nomination of development candidate Debio 0617B in oncology
Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies
Financement de Bourses d’excellence Debiopharm à l’EPFL et création de la ‘Debiopharm academy’
Cenix BioScience and Debiopharm Group™ collaborate to identify predictive biomarkers
Oncotest GmbH and Debiopharm Group™ announce a successful partnership in the identification of biomarker candidates
Debiopharm Group™ to support Ascepion in the development of Debio 1144 for the treatment of Chinese cancer patients
Shasun Pharmaceuticals Ltd and Debiopharm Group™ enter into licensing agreement for the manufacturing and commercialization of Huperzine-A
Debiopharm Group participates in first round of financing for compliant concept, an Empa and ETH Zurich spin-off bound for success…
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.